Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MNOV
- Price
- 1.66
- Stock movement down
- -0.02 (-1.19%)
- Company name
- MediciNova Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 81.58M
- Ent value
- 52.63M
- Price/Sales
- 316.31
- Price/Book
- 1.86
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -5.56%
- 1 year return (CAGR)
- -9.78%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MNOV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 316.31 |
| Price to Book | 1.86 |
| EV to Sales | 204.07 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.15M |
| EPS (TTM) | -0.24 |
| FCF per share (TTM) | -0.20 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 257.92K |
| Gross profit (TTM) | -31.06K |
| Operating income (TTM) | -13.37M |
| Net income (TTM) | -12.01M |
| EPS (TTM) | -0.24 |
| EPS (1y forward) | -0.38 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -12.04% |
| Operating margin (TTM) | -5185.49% |
| Profit margin (TTM) | -4656.65% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.56M |
| Net receivables | 0.00 |
| Total current assets | 32.92M |
| Goodwill | 9.60M |
| Intangible assets | 4.80M |
| Property, plant and equipment | 236.63K |
| Total assets | 47.58M |
| Accounts payable | 745.96K |
| Short/Current long term debt | 255.15K |
| Total current liabilities | 3.34M |
| Total liabilities | 3.61M |
| Shareholder's equity | 43.96M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.72M |
| Capital expenditures (TTM) | 2.90K |
| Free cash flow (TTM) | -9.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -27.32% |
| Return on Assets | -25.24% |
| Return on Invested Capital | -27.21% |
| Cash Return on Invested Capital | -22.04% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.59 |
| Daily high | 1.69 |
| Daily low | 1.55 |
| Daily Volume | 91K |
| All-time high | 14.28 |
| 1y analyst estimate | 7.00 |
| Beta | 0.48 |
| EPS (TTM) | -0.24 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| MNOV | S&P500 | |
| Current price drop from All-time high | -88.38% | -0.89% |
| Highest price drop | -91.74% | -19.00% |
| Date of highest drop | 29 Oct 2025 | 8 Apr 2025 |
| Avg drop from high | -89.17% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
81.58M
Marketcap category
Small-cap
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Employees
13
Website
Investor relations
-
SEC filings
CEO
Yuichi Iwaki
Country
USA
City
La Jolla
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page